Skip to main content

Advertisement

SpringerLink
Log in

Treatment Strategies in ANCA-Associated Vasculitis

  • Vasculitis (L Espinoza, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The long-term survival of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has improved dramatically as a direct result of evolving therapy. This review summarizes evidence-based treatment strategies with currently approved immunosuppressive medications to serve as a guide for practitioners in the management of patients with AAV.

Recent Findings

Targeted therapy aimed at minimizing treatment-related adverse effects while optimizing effectiveness is a propagated approach. Such tailored therapy considers disease severity and is especially warranted in those at high risk for relapsing vasculitis.

Summary

As treatment options for AAV become available, the need to tailor therapy has become increasingly relevant to optimize patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lane SE, Watts R, Scott DGI. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–5. https://doi.org/10.1007/s11926-005-0036-5.

    Article  PubMed  Google Scholar 

  2. Al-Hussain T, Hussein M, Conca W, Al Mana H, Akhtar M. Pathophysiology of ANCA-associated Vasculitis. Adv Anat Pathol. 2017;24(4):226–34. https://doi.org/10.1097/PAP.0000000000000154.

    Article  PubMed  Google Scholar 

  3. • Smith R, Jones R, Jayne D. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012;14(2):210. https://doi.org/10.1186/ar3797 This article provides a detailed review of commonly used immunosuppressive agents as therapeutic options for AAV based on randomized and nonrandomized studies.

    Article  CAS  Google Scholar 

  4. Mukhtyar C. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004–10. https://doi.org/10.1136/ard.2007.071936.

    Article  CAS  PubMed  Google Scholar 

  5. Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa J-J, Kyndt X, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheum. 2016;68(3):690–701. https://doi.org/10.1002/art.39450.

    Article  CAS  Google Scholar 

  6. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98. https://doi.org/10.7326/0003-4819-116-6-488.

    Article  CAS  PubMed  Google Scholar 

  7. Walsh M, Merkel P, Jayne D. The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis. ACR abstract 2788. 2018.

  8. Salvadori M. Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: open challenges in the remission induction therapy. World J Nephrol. 2018;7(3):71–83. https://doi.org/10.5527/wjn.v7.i3.71.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Puechal X. Targeted immunotherapy strategies in ANCA-associated vasculitis. Joint Bone Spine. 2018;(18):30285–9. https://doi.org/10.1016/j.jbspin.2018.09.002.

    Article  Google Scholar 

  10. •• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. https://doi.org/10.1056/NEJMoa0909905 This is one of two studies that revolutionized remission induction therapy for AAV by introducing Rituximab as an option to traditional cyclophosphamide.

    Article  CAS  Google Scholar 

  11. •• Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. https://doi.org/10.1056/NEJMoa0909169 This study revolutionized remission induction therapy for AAV by providing an option to traditional cyclophosphamide even in patients with significant renal impairment.

    Article  CAS  Google Scholar 

  12. • Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019; annrheumdis-2018-214245. https://doi.org/10.1136/annrheumdis-2018-214245 Results from this study support a role for mycophenolate mofetil in AAV especially as a consideration for remission induction in a subset of patients.

    Article  Google Scholar 

  13. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94. https://doi.org/10.1136/annrheumdis-2016-209133.

    Article  CAS  PubMed  Google Scholar 

  14. Sinico RA. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477–82. https://doi.org/10.1016/j.autrev.2012.08.006.

    Article  CAS  PubMed  Google Scholar 

  15. • Jayne D. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8. https://doi.org/10.1681/ASN.2007010090 The role of plasma exchange in AAV is controversial however as one of the largest randomized studies on this treatment modality, this study supports plasma exchange in patients with renal vasculitis.

    Article  CAS  Google Scholar 

  16. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33. https://doi.org/10.1136/ard.2011.153601.

    Article  CAS  PubMed  Google Scholar 

  17. Falk R, Merkel P. Granulomatosis with polyangiitis and microscopic polyangiitis: treatment of resistant disease. UpToDate [internet]. 2019 [cited 2019 Mar 9]; Available from: https://www.uptodate.com/contents/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-treatment-of-resistant-disease. Accessed March 9, 2019.

  18. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62(8):1166–73. https://doi.org/10.1002/acr.20176.

    Article  Google Scholar 

  19. • Pagnoux C, Mahr A, Hamidou MA, Boffa J-J, Ruivard M, Ducroix J-P, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803. https://doi.org/10.1056/NEJMoa0802311 This study demonstrated equivalency of azathioprine and methotrexate as agents for remission maintenance in AAV.

    Article  CAS  Google Scholar 

  20. • Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate Mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8. https://doi.org/10.1001/jama.2010.1658 This is one of several studies evaluating mycophenolate mofetil as effective therapy for remission maintenance.

    Article  CAS  Google Scholar 

  21. •• Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80. https://doi.org/10.1056/NEJMoa1404231 This study extended the indication for Rituximab in AAV to include maintenance of remission by demonstrating superiority over azathioprine in this regard.

    Article  Google Scholar 

  22. • Karras A, Pagnoux C, Haubitz M. Groot K de, Puechal X, Tervaert JWC, et al. randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662–8. https://doi.org/10.1136/annrheumdis-2017-211123 This trial provides important information regarding the optimal duration of therapy to prevent disease relapse in AAV.

    Article  CAS  Google Scholar 

  23. Fussner L. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheum. 2016;68(7):1700–10. https://doi.org/10.1002/art.39637.

    Article  CAS  Google Scholar 

  24. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–27. https://doi.org/10.1056/NEJMoa1213277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. • Charles P. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1144–50. https://doi.org/10.1136/annrheumdis-2017-212878 This study explored dosing regimens for Rituximab in remission maintenance of AAV.

Download references

Author information

Authors and Affiliations

  1. Rheumatology Section, Southeast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA, 70119, USA

    Nkechinyere Emejuaiwe

Authors
  1. Nkechinyere Emejuaiwe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nkechinyere Emejuaiwe.

Ethics declarations

Conflict of Interest

The author declares no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Vasculitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emejuaiwe, N. Treatment Strategies in ANCA-Associated Vasculitis. Curr Rheumatol Rep 21, 33 (2019). https://doi.org/10.1007/s11926-019-0835-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-019-0835-8

Keywords

Search

Navigation